AIM: To investigate the characteristics of patients with Kawasaki disease who needed intravenous gamma-globulin (IVGG) re-treatment. METHODS: Using the database of the 17th nationwide survey in Japan, a total 11,366 patients were identified and analysed (1,855 re-treatment patients and 9,511 responders). RESULTS: Multivariate logistic regression analysis showed that male sex (odds ratio (OR) 1.26; 95% CI 1.14-1.40), complete cases (OR 1.39; 95% CI 1.07-1.80), recurrence (OR 1.47; 95% CI 1.15-1.88), IVGG treatment within 4 d of illness (OR 2.05; 95% CI 1.84-2.27), daily dose of initial IVGG less than 1,000 mg/Kg (OR 0.54; 95% CI 0.48-0.61), exanthema (OR 2.03; 95% CI 1.62-2.56), lips and oral lesions (OR 1.57; 95% CI 1.24-1.98), peripheral extremities changes (OR 1.85; 95% CI 1.54-2.22), and cervical lymphadenopathy (OR 1.89; 95% CI 1.66-2.16) were independent risk factors associated with the need for IVGG re-treatment. CONCLUSION: Male sex, recurrence, and treatment with IVGG at a dose of 1,000 mg/d or less within 4 d of illness onset are independent risk factors associated with the need for IVGG re-treatment.
AIM: To investigate the characteristics of patients with Kawasaki disease who needed intravenous gamma-globulin (IVGG) re-treatment. METHODS: Using the database of the 17th nationwide survey in Japan, a total 11,366 patients were identified and analysed (1,855 re-treatment patients and 9,511 responders). RESULTS: Multivariate logistic regression analysis showed that male sex (odds ratio (OR) 1.26; 95% CI 1.14-1.40), complete cases (OR 1.39; 95% CI 1.07-1.80), recurrence (OR 1.47; 95% CI 1.15-1.88), IVGG treatment within 4 d of illness (OR 2.05; 95% CI 1.84-2.27), daily dose of initial IVGG less than 1,000 mg/Kg (OR 0.54; 95% CI 0.48-0.61), exanthema (OR 2.03; 95% CI 1.62-2.56), lips and oral lesions (OR 1.57; 95% CI 1.24-1.98), peripheral extremities changes (OR 1.85; 95% CI 1.54-2.22), and cervical lymphadenopathy (OR 1.89; 95% CI 1.66-2.16) were independent risk factors associated with the need for IVGG re-treatment. CONCLUSION: Male sex, recurrence, and treatment with IVGG at a dose of 1,000 mg/d or less within 4 d of illness onset are independent risk factors associated with the need for IVGG re-treatment.
Authors: Daniel Phadke; Sonali S Patel; Samuel R Dominguez; Heather Heizer; Marsha S Anderson; Mary P Glode; Pei-Ni Jone Journal: Pediatr Cardiol Date: 2015-05-21 Impact factor: 1.655
Authors: Pei-Ni Jone; Marsha S Anderson; Matthew J Mulvahill; Heather Heizer; Mary P Glodé; Samuel R Dominguez Journal: Pediatr Infect Dis J Date: 2018-10 Impact factor: 2.129
Authors: Lynn A Sleeper; L Luann Minich; Brian M McCrindle; Jennifer S Li; Wilbert Mason; Steven D Colan; Andrew M Atz; Beth F Printz; Annette Baker; Victoria L Vetter; Jane W Newburger Journal: J Pediatr Date: 2010-12-18 Impact factor: 4.406
Authors: Sang Hun Lee; Kyung Ok Ko; Jae Woo Lim; Jung Min Yoon; Young Hwa Song; Jong Wook Lee; Eun Jung Cheon Journal: Rheumatol Int Date: 2019-09-23 Impact factor: 2.631